An anti-MMR nanobody radiolabeled with 68Ga-NOTA has entered phase II clinical trials for imaging of MMR-expressing macrophages in head and neck squamous cell carcinoma as well as HL and NHL. The gene discussed is MRC1; the disease is head and neck squamous cell carcinoma.